{"id":4596,"date":"2026-06-01T13:04:09","date_gmt":"2026-06-01T13:04:09","guid":{"rendered":"https:\/\/bangbizarre.com\/index.php\/2026\/06\/01\/weight-loss-drugs-reduce-the-brains-desire-for-sex-and-alcohol\/"},"modified":"2026-06-01T13:04:10","modified_gmt":"2026-06-01T13:04:10","slug":"weight-loss-drugs-reduce-the-brains-desire-for-sex-and-alcohol","status":"publish","type":"post","link":"https:\/\/bangbizarre.com\/index.php\/2026\/06\/01\/weight-loss-drugs-reduce-the-brains-desire-for-sex-and-alcohol\/","title":{"rendered":"Weight-loss drugs reduce the brain's desire for sex and alcohol"},"content":{"rendered":"

2026-06-01 13:04:08<\/b>
\n
Weight-loss drugs may be rewiring the brain in ways far beyond shrinking waistlines.

\nNew research suggests medications like Ozempic, Wegovy and Mounjaro could reduce not only hunger but also cravings for sex, alcohol and even gambling.

\nThe drugs, known as GLP-1 agonists, were originally developed to treat type 2 diabetes but have become famous for helping patients lose weight by mimicking a natural hormone that slows digestion and signals fullness.

\nNow researchers at the University of Virginia believe they may also reshape the brain\u2019s reward system.

\nThe study, published in Nature, focused on a new generation of oral GLP-1 drugs and found they directly influenced brain circuits linked to pleasure, motivation and cravings.

\nScientists tested oral drugs danuglipron and orforglipron, developed by Pfizer and Eli Lilly, using genetically engineered mice whose GLP-1 brain receptors closely resemble those in humans.

\nResearchers discovered the drugs not only acted on the hindbrain, which controls fullness and nausea, but also triggered a pathway connecting to the central amygdala and dopamine-producing neurons.

\nDopamine is often called the brain\u2019s “feel-good” chemical and plays a key role in reward and addictive behaviours.

\nLead author Dr Ali D. G\u00fcler said: “This is just the beginning.

\n“If we understand these pathways, we may be able to design treatments that target specific behaviors \u2014 whether that\u2019s overeating, addiction or something else entirely.

\n“If these drugs are affecting reward pathways in the brain, that has implications beyond weight loss. It could influence things like addiction, impulse control or even how people experience pleasure.”

\nThe findings may help explain why some users report losing interest in habits and pleasures beyond food.

\nDr G\u00fcler said: “What we show is that these drugs can reduce not just hunger, but the desire to pursue rewarding food.

\n“They\u2019re acting on the system that makes you want the cake, not just the system that makes you feel full.”

\nAround one in eight US adults have reportedly taken GLP-1 drugs at least once.

\nWhile the research was conducted in mice, scientists believe it offers valuable clues about how the medications work in humans.

\nDr G\u00fcler added: “These are powerful compounds. We need to understand them fully as they move into everyday use.”
\n
Visit Bang Bizarre (main website) <\/a>
\n